-
LEAP: The latent exchangeability prior for borrowing information from historical data
Authors:
Ethan M. Alt,
Xiuya Chang,
Xun Jiang,
Qing Liu,
May Mo,
H. Amy Xia,
Joseph G. Ibrahim
Abstract:
It is becoming increasingly popular to elicit informative priors on the basis of historical data. Popular existing priors, including the power prior, commensurate prior, and robust meta-analytic prior provide blanket discounting. Thus, if only a subset of participants in the historical data are exchangeable with the current data, these priors may not be appropriate. In order to combat this issue,…
▽ More
It is becoming increasingly popular to elicit informative priors on the basis of historical data. Popular existing priors, including the power prior, commensurate prior, and robust meta-analytic prior provide blanket discounting. Thus, if only a subset of participants in the historical data are exchangeable with the current data, these priors may not be appropriate. In order to combat this issue, propensity score (PS) approaches have been proposed. However, PS approaches are only concerned with the covariate distribution, whereas exchangeability is typically assessed with parameters pertaining to the outcome. In this paper, we introduce the latent exchangeability prior (LEAP), where observations in the historical data are classified into exchangeable and non-exchangeable groups. The LEAP discounts the historical data by identifying the most relevant subjects from the historical data. We compare our proposed approach against alternative approaches in simulations and present a case study using our proposed prior to augment a control arm in a phase 3 clinical trial in plaque psoriasis with an unbalanced randomization scheme.
△ Less
Submitted 9 March, 2023;
originally announced March 2023.
-
A Survival Mediation Model with Bayesian Model Averaging
Authors:
Jie Zhou,
Xun Jiang,
H. Amy Xia,
Peng Wei,
Brian P. Hobbs
Abstract:
Determining the extent to which a patient is benefiting from cancer therapy is challenging. Criteria for quantifying the extent of "tumor response" observed within a few cycles of treatment have been established for various types of solid as well as hematologic malignancies. These measures comprise the primary endpoints of phase II trials. Regulatory approvals of new cancer therapies, however, are…
▽ More
Determining the extent to which a patient is benefiting from cancer therapy is challenging. Criteria for quantifying the extent of "tumor response" observed within a few cycles of treatment have been established for various types of solid as well as hematologic malignancies. These measures comprise the primary endpoints of phase II trials. Regulatory approvals of new cancer therapies, however, are usually contingent upon the demonstration of superior overall survival with randomized evidence acquired with a phase III trial comparing the novel therapy to an appropriate standard of care treatment. With nearly two thirds of phase III oncology trials failing to achieve statistically significant results, researchers continue to refine and propose new surrogate endpoints. This article presents a Bayesian framework for studying relationships among treatment, patient subgroups, tumor response and survival. Combining classical components of mediation analysis with Bayesian model averaging (BMA), the methodology is robust to model mis-specification among various possible relationships among the observable entities. Posterior inference is demonstrated via application to a randomized controlled phase III trial in metastatic colorectal cancer. Moreover, the article details posterior predictive distributions of survival and statistical metrics for quantifying the extent of direct and indirect, or tumor response mediated, treatment effects.
△ Less
Submitted 16 September, 2020;
originally announced September 2020.
-
Analyzing Basket Trials under Multisource Exchangeability Assumptions
Authors:
Michael J. Kane,
Nan Chen,
Alexander M. Kaizer,
Xun Jiang,
H. Amy Xia,
Brian P. Hobbs
Abstract:
Basket designs are prospective clinical trials that are devised with the hypothesis that the presence of selected molecular features determine a patient's subsequent response to a particular "targeted" treatment strategy. Basket trials are designed to enroll multiple clinical subpopulations to which it is assumed that the therapy in question offers beneficial efficacy in the presence of the target…
▽ More
Basket designs are prospective clinical trials that are devised with the hypothesis that the presence of selected molecular features determine a patient's subsequent response to a particular "targeted" treatment strategy. Basket trials are designed to enroll multiple clinical subpopulations to which it is assumed that the therapy in question offers beneficial efficacy in the presence of the targeted molecular profile. The treatment, however, may not offer acceptable efficacy to all subpopulations enrolled. Moreover, for rare disease settings, such as oncology wherein these trials have become popular, marginal measures of statistical evidence are difficult to interpret for sparsely enrolled subpopulations. Consequently, basket trials pose challenges to the traditional paradigm for trial design, which assumes inter-patient exchangeability. The R-package \pkg{basket} facilitates the analysis of basket trials by implementing multi-source exchangeability models. By evaluating all possible pairwise exchangeability relationships, this hierarchical modeling framework facilitates Bayesian posterior shrinkage among a collection of discrete and pre-specified subpopulations. Analysis functions are provided to implement posterior inference of the response rates and all possible exchangeability relationships between subpopulations. In addition, the package can identify "poolable" subsets of and report their response characteristics. The functionality of the package is demonstrated using data from an oncology study with subpopulations defined by tumor histology.
△ Less
Submitted 1 August, 2019;
originally announced August 2019.
